Celyad reports 'promising' early results at first dose level of THINK trial
Celyad announces promising early clinical results at the 3-month follow-up of the first dose-level in the solid tumor arm of the THINK trial. At the first cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer, or mCRC, patients, who were progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease, or SD, according to RECIST criteria at three months. According to recent studies conducted on similar patient populations, median progression free survival in these patients under standard of care is between 1.9 and 3.2 months. The third patient, a refractory pancreatic patient, was in progression at the same time point. No toxicity signals were observed in any of the patients.